Autolus Therapeutics PLC
NASDAQ:AUTL

Watchlist Manager
Autolus Therapeutics PLC Logo
Autolus Therapeutics PLC
NASDAQ:AUTL
Watchlist
Price: 2.1499 USD -1.38%
Market Cap: 572.1m USD
Have any thoughts about
Autolus Therapeutics PLC?
Write Note

Autolus Therapeutics PLC
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Autolus Therapeutics PLC
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Autolus Therapeutics PLC
NASDAQ:AUTL
Interest Income Expense
-$29m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Interest Income Expense
$570k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Exscientia PLC
NASDAQ:EXAI
Interest Income Expense
ÂŁ12.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Interest Income Expense
$27.8m
CAGR 3-Years
N/A
CAGR 5-Years
110%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Interest Income Expense
-ÂŁ344k
CAGR 3-Years
21%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Interest Income Expense
-ÂŁ200k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
24%
No Stocks Found

Autolus Therapeutics PLC
Glance View

Market Cap
572.1m USD
Industry
Biotechnology

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. The firm is focused on developing programmed T cell therapies for the treatment of cancer. The firm has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. Its lead clinical programs include AUTO1 (obecabtagene autoleucel, Obe-Cel), AUTO4, and AUTO6 / AUTO6NG. Obe-cel is a CD19 CAR T cell investigational therapy designed to overcome limitations in clinical activity and safety. Obe-cel reduces toxicity and is less prone to T cell exhaustion, which could improve persistence and the ability of programmed T cells to engage in serial killing of target cancer cells. AUTO4 is a T cell therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1. AUTO6 / AUTO6NG is a T cell therapy targeting GD2 in development for the treatment of neuroblastoma. Its other clinical programs include AUTO5, AUTO7, and AUTO8.

AUTL Intrinsic Value
5.0653 USD
Undervaluation 58%
Intrinsic Value
Price

See Also

What is Autolus Therapeutics PLC's Interest Income Expense?
Interest Income Expense
-29m USD

Based on the financial report for Dec 31, 2023, Autolus Therapeutics PLC's Interest Income Expense amounts to -29m USD.

What is Autolus Therapeutics PLC's Interest Income Expense growth rate?
Interest Income Expense CAGR 1Y
-436%

Over the last year, the Interest Income Expense growth was -436%.

Back to Top